{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:08:07Z","timestamp":1793142487648,"version":"4.5.0"},"reference-count":117,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health (NIH)","award":["K08CA279076-01"],"award-info":[{"award-number":["K08CA279076-01"]}]},{"name":"National Cancer Institute of the National Institutes of Health (NIH)","award":["NIH KL2 TR001856 [PI: Rubio]"],"award-info":[{"award-number":["NIH KL2 TR001856 [PI: Rubio]"]}]},{"name":"National Cancer Institute of the National Institutes of Health (NIH)","award":["K08CA263317"],"award-info":[{"award-number":["K08CA263317"]}]},{"name":"National Cancer Institute of the National Institutes of Health (NIH)","award":["U54CA163068"],"award-info":[{"award-number":["U54CA163068"]}]},{"name":"National Cancer Institute of the National Institutes of Health (NIH)","award":["U54CA163071"],"award-info":[{"award-number":["U54CA163071"]}]},{"name":"University of Pittsburgh","award":["K08CA279076-01"],"award-info":[{"award-number":["K08CA279076-01"]}],"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Pittsburgh","award":["NIH KL2 TR001856 [PI: Rubio]"],"award-info":[{"award-number":["NIH KL2 TR001856 [PI: Rubio]"]}],"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Pittsburgh","award":["K08CA263317"],"award-info":[{"award-number":["K08CA263317"]}],"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Pittsburgh","award":["U54CA163068"],"award-info":[{"award-number":["U54CA163068"]}],"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Pittsburgh","award":["U54CA163071"],"award-info":[{"award-number":["U54CA163071"]}],"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["K08CA279076-01"],"award-info":[{"award-number":["K08CA279076-01"]}]},{"name":"National Cancer Institute","award":["NIH KL2 TR001856 [PI: Rubio]"],"award-info":[{"award-number":["NIH KL2 TR001856 [PI: Rubio]"]}]},{"name":"National Cancer Institute","award":["K08CA263317"],"award-info":[{"award-number":["K08CA263317"]}]},{"name":"National Cancer Institute","award":["U54CA163068"],"award-info":[{"award-number":["U54CA163068"]}]},{"name":"National Cancer Institute","award":["U54CA163071"],"award-info":[{"award-number":["U54CA163071"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating symptom experienced by cancer survivors. Despite the burden of CIPN-related symptoms, interventions remain limited. Objectives: This narrative review seeks to propose a framework for CIPN predisposing, precipitating, and perpetuating factors (3Ps), which will provide a foundation for future research and clinical interventions aimed at mitigating CIPN-related symptoms and morbidity. Methods: A comprehensive literature search was performed using PubMed, guided by keywords related to \u201cchemotherapy-induced peripheral neuropathy.\u201d Studies were limited to those with full text available in English. Results: Predisposing factors outlined in this framework, such as older age and comorbid conditions, can be used to identify patients who have a higher risk of developing CIPN. The major precipitating factor of CIPN is the delivery of chemotherapy to peripheral nerves, which may be mitigated via cryotherapy or compression therapy during chemotherapy. Perpetuating factors can offer insight into psychological, cognitive, and behavioral modifications that could be treatment targets for CIPN management. Conclusion: The proposed 3P model can guide the development of effective interventions for CIPN by suggesting modifiable psychological and behavioral treatment targets that may mitigate the impact of CIPN for cancer patients.<\/jats:p>","DOI":"10.3390\/cancers16142571","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T10:39:26Z","timestamp":1721299166000},"page":"2571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-0885","authenticated-orcid":false,"given":"Kimberley T.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1005-0303","authenticated-orcid":false,"given":"Hailey W.","family":"Bulls","sequence":"additional","affiliation":[{"name":"Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-8132","authenticated-orcid":false,"given":"Aasha I.","family":"Hoogland","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"James","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-8261","authenticated-orcid":false,"given":"Claudia B.","family":"Colon-Echevarria","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Starobova, H., and Vetter, I. (2017). Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front. Mol. Neurosci., 10.","DOI":"10.3389\/fnmol.2017.00174"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jcrpr.2017.03.005","article-title":"Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment","volume":"4","author":"Marshall","year":"2017","journal-title":"J. Cancer Res. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy","volume":"125","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e12421","DOI":"10.1111\/ecc.12421","article-title":"Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): A secondary analysis of randomised controlled trial\u2014CALGB\/alliance 170601","volume":"26","author":"Smith","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_7","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.12788\/jcso.0086","article-title":"Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy","volume":"12","author":"Beijers","year":"2014","journal-title":"J. Community Support. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3747\/co.21.1984","article-title":"The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients","volume":"21","author":"Hong","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e12443","DOI":"10.1111\/ecc.12443","article-title":"The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: A qualitative thematic synthesis","volume":"26","author":"Tanay","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NSS.S18895","article-title":"Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer","volume":"4","author":"Palesh","year":"2012","journal-title":"Nat. Sci. Sleep"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0193-953X(18)30532-X","article-title":"A behavioral perspective on insomnia treatment","volume":"10","author":"Spielman","year":"1987","journal-title":"Psychiatr. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Crowder, S.L., Playdon, M.C., Gudenkauf, L.M., Ose, J., Gigic, B., Greathouse, L., Peoples, A.R., Sleight, A.G., Jim, H.S.L., and Figueiredo, J.C. (2022). A Molecular Approach to Understanding the Role of Diet in Cancer-Related Fatigue: Challenges and Future Opportunities. Nutrients, 14.","DOI":"10.3390\/nu14071496"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12955-020-01493-y","article-title":"Psychometric testing of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (FACT\/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy","volume":"18","author":"Cheng","year":"2020","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study","volume":"17","author":"Huang","year":"2007","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_18","first-page":"2787","article-title":"Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"Barton","year":"2013","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1188\/16.CJON.20-01AP","article-title":"Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature","volume":"20","author":"Curcio","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_20","unstructured":"National Cancer Institute (2019, June 22). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.pec.2019.04.012","article-title":"Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches","volume":"102","author":"Knoerl","year":"2019","journal-title":"Patient Educ. Couns."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/cncr.32175","article-title":"Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice","volume":"125","author":"Nyrop","year":"2019","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1212\/01.WNL.0000092015.03923.19","article-title":"Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale","volume":"61","author":"Cavaletti","year":"2003","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2016.2047","article-title":"Subjective or Objective Measures of Cognitive Functioning-What\u2019s More Important?","volume":"2","author":"Savard","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults with Cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2339116","DOI":"10.1001\/jamanetworkopen.2023.39116","article-title":"Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients","volume":"6","author":"Baltussen","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1516","DOI":"10.1634\/theoncologist.2019-0701","article-title":"Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study","volume":"25","author":"Feliu","year":"2020","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1634\/theoncologist.2017-0559","article-title":"Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors","volume":"23","author":"Nishijima","year":"2018","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Feliu, J., Espinosa, E., Basterretxea, L., Paredero, I., Llabres, E., Jimenez-Munarriz, B., Losada, B., Pinto, A., Custodio, A.B., and Munoz, M.D.M. (2021). Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy. Cancers, 13.","DOI":"10.3390\/cancers13061437"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/cncr.24981","article-title":"Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer","volume":"116","author":"Glendenning","year":"2010","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00520-013-2068-0","article-title":"Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations","volume":"22","author":"Griffith","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1188\/10.ONF.758-764","article-title":"Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments","volume":"37","author":"Kiser","year":"2010","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2036695","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy","volume":"4","author":"Mizrahi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2011.39.8446","article-title":"Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer","volume":"30","author":"Schneider","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1007\/s00520-019-04695-3","article-title":"Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors","volume":"27","author":"Wong","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CMAR.S44261","article-title":"Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature","volume":"6","author":"Argyriou","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ygyno.2018.12.002","article-title":"A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer","volume":"152","author":"Bulls","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/bja\/aen090","article-title":"Advances in understanding the mechanisms and management of persistent pain in older adults","volume":"101","author":"Karp","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1529-8027.2000.00026.x","article-title":"Influence of aging on peripheral nerve function and regeneration","volume":"5","author":"Verdu","year":"2000","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","article-title":"Sex differences in pain: A brief review of clinical and experimental findings","volume":"111","author":"Bartley","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jpain.2008.12.001","article-title":"Sex, gender, and pain: A review of recent clinical and experimental findings","volume":"10","author":"Fillingim","year":"2009","journal-title":"J. Pain Off. J. Am. Pain Soc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2019.08.010","article-title":"Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials","volume":"121","author":"Davidson","year":"2019","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-017-2927-8","article-title":"The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: Results from the population-based PROFILES registry","volume":"96","author":"Beijers","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3109\/10428194.2013.873535","article-title":"Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score","volume":"55","author":"Zaroulis","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0885-3924(94)90175-9","article-title":"Differences in postoperative pain severity among four ethnic groups","volume":"9","author":"Faucett","year":"1994","journal-title":"J. Pain Symptom Manag."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/art.38620","article-title":"Racial and ethnic differences in older adults with knee osteoarthritis","volume":"66","author":"Sibille","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/AJP.0000000000000462","article-title":"Ethnicity, Cortisol, and Experimental Pain Responses among Persons with Symptomatic Knee Osteoarthritis","volume":"33","author":"Herbert","year":"2017","journal-title":"Clin. J. Pain"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0304-3959(96)03215-0","article-title":"Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates","volume":"68","author":"Breitbart","year":"1996","journal-title":"Pain"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jpainsymman.2014.11.300","article-title":"Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients with Colorectal vs. Breast, Lung, or Prostate Cancer: Results from a Prospective Multicenter Study","volume":"49","author":"Lewis","year":"2015","journal-title":"J. Pain Symptom Manag."},{"key":"ref_51","first-page":"2763","article-title":"The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice","volume":"26","author":"Simon","year":"2017","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","article-title":"Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199","volume":"21","author":"Schneider","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"82244","DOI":"10.18632\/oncotarget.12545","article-title":"Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans","volume":"7","author":"Schneider","year":"2016","journal-title":"Oncotarget"},{"key":"ref_54","first-page":"179","article-title":"Factors Exacerbating Peripheral Neuropathy Induced by Paclitaxel Plus Carboplatin in Non-small Cell Lung Cancer","volume":"20","author":"Kawakami","year":"2012","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2017.08.028","article-title":"Cancer Pain with a Neuropathic Component: A Cross-sectional Study of Its Clinical Characteristics, Associated Psychological Distress, Treatments, and Predictors at Referral to a Cancer Pain Clinic","volume":"55","author":"Acharya","year":"2018","journal-title":"J. Pain Symptom Manag."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.7314\/APJCP.2015.16.17.7603","article-title":"Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran","volume":"16","author":"Fahimi","year":"2015","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000442527","article-title":"Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy","volume":"90","author":"Ottaiano","year":"2016","journal-title":"Oncology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00520-017-3571-5","article-title":"Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy","volume":"25","author":"Trahan","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"djx162","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant Chemotherapy: NRG Oncology\/NSABP B-30","volume":"110","author":"Bandos","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jpainsymman.2017.04.011","article-title":"Neuropathic Pain After Breast Cancer Treatment: Characterization and Risk Factors","volume":"54","author":"Pereira","year":"2017","journal-title":"J. Pain Symptom Manag."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00520-015-2935-y","article-title":"Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: A prospective cohort study","volume":"24","author":"Pereira","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2165\/00003495-200363150-00004","article-title":"Long-term complications of chemotherapy for germ cell tumours","volume":"63","author":"Chaudhary","year":"2003","journal-title":"Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00520-012-1667-5","article-title":"Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV","volume":"21","author":"Vincenzi","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kerckhove, N., Collin, A., Cond\u00e9, S., Chaleteix, C., Pezet, D., and Balayssac, D. (2017). Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00086"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ene.12353","article-title":"Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies","volume":"21","author":"Kroigard","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/pm\/pnx231","article-title":"Chronic Pain and Neuropathy Following Adjuvant Chemotherapy","volume":"19","author":"Ventzel","year":"2018","journal-title":"Pain Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","article-title":"Chemotherapy-induced pain and neuropathy: A prospective study in patients treated with adjuvant oxaliplatin or docetaxel","volume":"157","author":"Ventzel","year":"2016","journal-title":"Pain"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical Course of Oxaliplatin-Induced Neuropathy: Results from the Randomized Phase III Trial N08CB (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1007\/s00520-016-3373-1","article-title":"Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)","volume":"24","author":"Pachman","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/0284186X.2014.995775","article-title":"Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives","volume":"54","author":"Ewertz","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000443377","article-title":"Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer","volume":"90","author":"Wang","year":"2016","journal-title":"Oncology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cncr.10835","article-title":"Second-line, low-dose, weekly paclitaxel in patients with stage IIIB\/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel","volume":"95","author":"Socinski","year":"2002","journal-title":"Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00520-017-3631-x","article-title":"Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer","volume":"25","author":"Song","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1188\/13.CJON.S1.35-40","article-title":"Quality-of-life considerations with taxane-based therapy in metastatic breast cancer","volume":"17","author":"Maxwell","year":"2013","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF02968010","article-title":"Neurotoxicity of taxanes: Symptoms and quality of life assessment","volume":"11","author":"Kuroi","year":"2004","journal-title":"Breast Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00520-011-1127-7","article-title":"Falls in persons with chemotherapy-induced peripheral neuropathy","volume":"20","author":"Tofthagen","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00520-013-2004-3","article-title":"A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer","volume":"22","author":"Vatandoust","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/0284186X.2014.980912","article-title":"Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry","volume":"54","author":"Beijers","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: A comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1200\/JCO.21.02726","article-title":"Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients with Stage III Colon Cancer: An ACCENT\/IDEA Pooled Analysis of 11 Adjuvant Trials","volume":"41","author":"Gallois","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Muhammadzai, J., Haider, K., Moser, M., Chalchal, H., Shaw, J., Gardiner, D., Dueck, D.A., Ahmed, O., Brunet, B., and Iqbal, M. (2022). Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263250"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"100927","DOI":"10.1016\/j.gore.2022.100927","article-title":"Beneficial effects of exercise on chemotherapy-induced peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms","volume":"39","author":"Kundur","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1089\/ars.2011.4498","article-title":"Oxygen consumption and usage during physical exercise: The balance between oxidative stress and ROS-dependent adaptive signaling","volume":"18","author":"Radak","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Scheffer, D.D.L., and Latini, A. (2020). Exercise-induced immune system response: Anti-inflammatory status on peripheral and central organs. Biochim. Biophys. Acta Mol. Basis Dis., 1866.","DOI":"10.1016\/j.bbadis.2020.165823"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1545968319899918","article-title":"An Exploratory Randomized Trial of Physical Therapy for the Treatment of Chemotherapy-Induced Peripheral Neuropathy","volume":"34","author":"Pitz","year":"2020","journal-title":"Neurorehabil. Neural Repair."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","article-title":"A Randomized Controlled Trial to Assess the Effectiveness of Muscle Strengthening and Balancing Exercises on Chemotherapy-Induced Peripheral Neuropathic Pain and Quality of Life Among Cancer Patients","volume":"43","author":"Dhawan","year":"2020","journal-title":"Cancer Nurs."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11764-022-01182-3","article-title":"Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: A systematic review and meta-analysis","volume":"17","author":"Guo","year":"2023","journal-title":"J. Cancer Surviv. Res. Pract."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Kneis, S., Wehrle, A., Muller, J., Maurer, C., Ihorst, G., Gollhofer, A., and Bertz, H. (2019). It\u2019s never too late\u2014Balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: Results of a randomized controlled trial. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5522-7"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41416-021-01471-1","article-title":"Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: A randomised-controlled trial","volume":"125","author":"Muller","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jbmt.2021.07.013","article-title":"Effects of foam pad balance exercises on cancer patients undergoing chemotherapy: A randomized control trial","volume":"28","author":"Saraboon","year":"2021","journal-title":"J. Bodyw. Mov. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00520-017-3875-5","article-title":"Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: A randomized controlled trial","volume":"26","author":"Zimmer","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/j.pain.0000000000000131","article-title":"Sleep and pain sensitivity in adults","volume":"156","author":"Sivertsen","year":"2015","journal-title":"Pain"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","article-title":"Oxaliplatin-induced peripheral neuropathy\u2019s effects on health-related quality of life of colorectal cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2014.09.016","article-title":"Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry","volume":"135","author":"Ezendam","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/abm\/kaaa101","article-title":"Lagged relationships among chemotherapy-induced peripheral neuropathy, sleep quality, and physical activity during and after chemotherapy","volume":"55","author":"Bulls","year":"2021","journal-title":"Ann. Behav. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e390428","DOI":"10.1200\/EDBK_390428","article-title":"Improving Quality of Life During Chemotherapy: Cannabinoids, Cryotherapy, and Scalp Cooling","volume":"43","author":"Michel","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.annonc.2019.09.006","article-title":"Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy","volume":"31","author":"Beijers","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-016-3977-7","article-title":"Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata Breast Cancer Study Group","volume":"160","author":"Tsuyuki","year":"2016","journal-title":"Breast Cancer Res. Res. Treat."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Kotani, H., Terada, M., Mori, M., Horisawa, N., Sugino, K., Kataoka, A., Adachi, Y., Gondou, N., Yoshimura, A., and Hattori, M. (2021). Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: Results from a double-blind phase 2 trial. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08240-6"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00520-017-4013-0","article-title":"Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: A multicenter, randomized controlled trial","volume":"26","author":"Kleckner","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1534735419836501","DOI":"10.1177\/1534735419836501","article-title":"A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy","volume":"18","author":"Molassiotis","year":"2019","journal-title":"Integr. Cancer Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1634\/theoncologist.2019-0489","article-title":"Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial","volume":"25","author":"Lu","year":"2020","journal-title":"Oncologist"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra2110098","article-title":"Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain","volume":"389","author":"Smith","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpainsymman.2011.03.015","article-title":"Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: Results of a pilot, randomized, controlled trial","volume":"43","author":"Marineo","year":"2012","journal-title":"J. Pain Symptom Manag."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/ACO.0000000000001073","article-title":"Scrambler therapy for noncancer neuropathic pain: A focused review","volume":"34","author":"Abdi","year":"2021","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e1900","DOI":"10.1212\/WNL.0000000000009370","article-title":"Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial","volume":"94","author":"Mealy","year":"2020","journal-title":"Neurology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e21710","DOI":"10.1200\/JCO.2017.35.15_suppl.e21710","article-title":"Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy (CIPN): A multicenter, single blind, randomized, wait-list controlled trial","volume":"35","author":"Knoerl","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:18:53Z","timestamp":1760109533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":117,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142571"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142571","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}